New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention ...

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to ...

Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP ...

At Sanofi, we chase the miracles of science to improve people’s lives. And digital is at the heart of our ambition to transform the practice of medicine. We believe that with artificial intelligence, ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

As a Sanofi shareholder, you own a share in our capital, providing us with the resources we need to grow. By investing in our future, you are giving us a vote of confidence. Confidence is the ...

The Sanofi General Meeting will be held on April 30, 2024 at 02:30pm (CET) in the “Blue Amphitheatre” at the Palais des Congrès in Paris, Porte Maillot. For any questions relating to this event, you ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Barbara Lavernos has spent her entire career with L’Oréal, whom she joined in 1991. In 2004, she was appointed Global Chief Procurement Officer, and was Managing Director of Travel Retail in 2011. In ...

Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis 96% of participants receiving high-dose intravenous frexalimab ...

Sauf indication contraire, l’évolution du CA est exprimée à taux de change constants (TCC) (voir la définition Annexe 9) (1) Le commentaire du compte de résultat net des activités, indicateur non-IFRS ...